History, however, offers a useful caution. Breakthrough technologies in medicine rarely achieve their full potential simply because they exist. Their real impact depends on whether the institutions responsible for health-care delivery know how to adopt them wisely, integrate them responsibly and align them with their mission to improve patient health.

Artificial intelligence now stands at that same threshold. The industry has moved beyond fascination with what algorithms can do and entered a more demanding phase: determining how these tools should be evaluated, governed, and integrated into the environments where care is delivered. At the same time, some health professionals are turning to AI – not to augment their knowledge – but assuming the information is patient-care ready.

Across the health ecosystem, leaders are discovering that the most important questions about artificial intelligence are not technological. They are organizational, ethical and operational. Which AI systems genuinely improve clinical decision-making? Which tools strengthen the efficiency of hospitals and health systems? Which innovations introduce complexity without delivering measurable benefit?

Answering those questions requires a perspective that bridges policy leadership, real-world care delivery, and the scientific foundations of biomedical informatics. That convergence of experience sits at the center of a “Views From the Top” mainstage discussion at the HIMSS Global Health Conference & Exhibition, where some 35,000 leaders whose work spans the global health ecosystem will examine how organizations can recognize the true value proposition of artificial intelligence applications before embedding them into health-care systems.

The perspectives shaping this discussion reflect three essential dimensions of responsible artificial intelligence in health: governance frameworks that guide innovation, operational insights from large-scale health care delivery, and scientific rigor grounded in biomedical informatics. Together, these vantage points illuminate the path from technological promise to practical value.

Governing Innovation in a Rapidly Changing Health Ecosystem

Digital transformation in health rarely succeeds simply because technology exists. It succeeds when organizations develop leadership frameworks capable of evaluating innovation, managing risk and aligning new tools with patient-centered goals.

Few leaders have observed the evolution of digital health across as many national systems and institutional environments as Hal Wolf, president and chief executive officer of HIMSS, Ran Balicer, MD, PhD, chief innovation officer of Clalit Health Services and Isaac Kohane, MD, PhD, chair of biomedical informatics at Harvard Medical School. The three will step onto the mainstage at HIMSS to share their “View from the Top” in a session titled: “Recognizing the ‘Value Proposition’ Criteria While Selecting AI Applications.”

Through his work with global government health ministries, hospital networks, and technology innovators worldwide, Wolf has consistently emphasized that technological progress must be anchored in governance and trust.

“Digital health transformation is not about technology alone. It is about leadership, governance, and the trust that allows innovation to improve care,” Wolf has said in discussions about global digital health transformation.

Artificial intelligence intensifies this leadership challenge because its influence extends far beyond traditional clinical tools. AI systems increasingly operate across multiple layers of healthcare delivery. Some applications assist clinicians by analyzing medical data or suggesting treatment options. Others function within hospitals’ and health systems’ operational infrastructure, helping manage patient flow, prioritize diagnostic reviews, and allocate scarce resources.

These operational algorithms rarely capture headlines; however,  they shape the environment in which health care is delivered. Decisions about which cases are reviewed first, how clinicians allocate their attention, and how health systems manage capacity can profoundly influence patient outcomes.

For leaders responsible for health systems, artificial intelligence cannot be treated as simply another technological upgrade. It must be evaluated through governance structures capable of understanding how algorithms function, what assumptions shape their recommendations, and how their use aligns with institutional priorities.

Without that oversight, innovation risks amplifying complexity rather than improving care. Instead of informing, it can spread misinformation.

Aligning Artificial Intelligence With the Values of Medicine

Governance provides the policy foundation for responsible adoption of artificial intelligence, but real-world implementation reveals a second challenge: ensuring that AI systems operate effectively within healthcare delivery itself.

Large population health systems increasingly use advanced analytics to anticipate risk, manage chronic disease, and allocate clinical resources across diverse communities. Within these environments, artificial intelligence is no longer a theoretical innovation. It is already influencing how health organizations prioritize patients, coordinate care and deploy limited resources.

That operational perspective is central to Ran Balicer, MD, PhD, of Clalit Health Services, one of the world’s most advanced data-driven health systems. The Clalit integrated infrastructure connects hospitals, clinics, and community health programs through longitudinal datasets that support predictive analytics at the national scale.

Experience within such systems reinforces an important insight: artificial intelligence models do not function independently of human judgment. They reflect priorities embedded in their design and the assumptions guiding their deployment.

“Algorithms are opinions embedded in code,” Balicer has observed in discussions about the role of artificial intelligence in population health.

In practice, this means that AI systems interpret clinical data through frameworks shaped by human choices. The way a model defines risk, prioritizes cases, or recommends interventions reflects decisions about what matters most within a healthcare environment.

Those decisions carry ethical implications. When artificial intelligence helps determine which patients receive immediate attention or which cases are escalated for further review, transparency about how algorithms function becomes essential to maintaining trust among clinicians and patients alike. The scientific frontier of health-care AI reinforces that concern.

Isaac Kohane, MD, PhD, who has also served as a co-author of the Institute of Medicine Report on Precision Medicine, which has served as the template for national efforts, has spent decades exploring how machine learning can advance medicine while preserving the judgment that defines clinical practice. His research emphasizes that artificial intelligence in healthcare must align with the ethical traditions and professional responsibilities of medicine.

“AI systems in medicine must ultimately reflect the values of the profession they serve,” Kohane has written in discussions about AI alignment in biomedical informatics.

This perspective highlights a crucial distinction between technological capability and clinical responsibility. Many AI models entering healthcare environments were originally designed for broader computational tasks rather than the nuanced realities of patient care. Medicine operates within a landscape shaped by uncertainty, empathy, and accountability, and technologies introduced into that environment must reflect those values.

Ensuring that artificial intelligence aligns with the principles guiding health-care delivery, therefore, represents one of the most important scientific and ethical challenges facing the future of health.

The Discipline Required to Make Innovation Matter

The health sector has experienced waves of technological enthusiasm before. Electronic health records promised seamless information exchange, but then introduced administrative burdens on health professionals when implemented without thoughtful workflow design. Data analytics promised unprecedented insight, but sometimes led to fragmentation when systems failed to communicate across institutions.

Artificial intelligence now stands at a similar moment in the evolution of health technology.

Its capabilities in supporting decision-making flow are extraordinary, yet realizing them will require disciplined leadership to evaluate, integrate and govern AI tools within health-care delivery systems. Health leaders must learn to ask deeper questions before embracing the next algorithmic breakthrough. What problem does this system truly solve? How does it strengthen clinical practice? What assumptions guide its recommendations? How does its use advance the mission of improving patient health?

These questions move the conversation beyond technological novelty toward operational practicality. It’s among the many reasons these three global leaders step to the HIMSS stage together.

Artificial intelligence will undoubtedly reshape the health ecosystem in the years ahead. Its long-term impact, however, will not be determined solely by the sophistication of algorithms or the speed of technological progress. Along with how to leverage AI, ChatGPT and LLMs, users require heightened cognitive awareness.

It will be determined by whether the health community develops the discipline and ability required to translate innovation into systems that strengthen care, support clinicians and improve the health of the populations they serve.

The real story of artificial intelligence in health is no longer about what machines can do. It is about how wisely the health sector chooses to use them.

The post From AI Excitement to Execution: Why Health Leaders Must Now Master the “How” appeared first on Medika Life.

The country’s trajectory has been building for years. A fast-growing middle-income population, rising chronic disease burden, and expanding health infrastructure have created both demand and urgency. What is changing now is the environment in which innovation can move, driving faster approvals, a culture of collaboration, digital infrastructure and a government signaling policy readiness to engage global partners in shaping the next era of medicine.

The economic momentum is significant. The Indian health ecosystem has expanded from roughly $372 billion in 2023 to $638 billion in 2025, making it one of the fastest-growing major health markets in the world. The broader industry is expected to exceed $610 billion by 2026, fueled by rising insurance coverage, expanding hospital infrastructure, and growing demand for chronic disease management. Health growth in India continues at approximately 10–12 percent annually, well above the growth rates typical of mature markets, reflecting both rising access and structural transformation.

BIOAsia 2026 reflects this inflection point. The global gathering in Hyderabad, themed “TechBio Unleashed: AI, Automation & the Biology Revolution,” highlights the (bio)convergence of biology, data, and intelligent systems reshaping health worldwide. Organizers emphasize that the meeting aims to drive health transformation and reinforce India’s position as a leading global life sciences force. For multinational innovators, the message is increasingly clear: India is not only where innovation is deployed; it is also where it is developed. It is where innovation is increasingly defined. India has become a go-to market for multinational enterprises.

Policy Signals and Market Scale: From Opportunity to Strategic Partnership

India’s regulatory and policy environment is evolving in ways that matter deeply to multinational innovators. One pivotal shift came with the country’s decision to allow certain medicines approved in specified developed markets to launch without local clinical trials, a move designed to accelerate patient access while aligning more closely with global regulatory science. This policy shift reflected confidence in international data, a commitment to innovation, and recognition that faster access must remain central to national health strategy.

The scale of India’s pharmaceutical and life sciences market reinforces this transformation. The pharmaceutical sector reached approximately $68 billion in 2025 and is projected to grow to more than $170 billion during the next decade, driven by expanding middle-income demand and strong domestic manufacturing. India already supplies roughly one-fifth of the world’s generic medicines. It produces the majority of global vaccines by volume, positioning the country as a central player in global health supply chains.

As Aman Gupta of SPAG/FINN wrote in Medika Life, “India’s health sector is undergoing a profound transformation, bolstered by government-led reforms and a favorable FDI regime. The allowance of 100% foreign direct investment through automatic routes in health and related sectors has already attracted global giants.” His observation reinforces a central reality for multinational innovators: India’s policy environment is increasingly designed not only to welcome global participation, but to encourage long-term strategic partnership in building the future of healthcare.

Investment trends tell the same story. Health and pharmaceutical private equity and venture investments have reached multi-billion-dollar levels annually. At the same time, India’s contract drug development and manufacturing sector is projected to exceed $22 billion within the next decade. These dynamics position India as a growth market and as a strategic partner across the innovation lifecycle from discovery and clinical development to manufacturing and global distribution.

Shakthi Nagappan, CEO of Telangana Life Sciences Foundation, captured this moment clearly, noting that BIOAsia arrives at a time when technology and biology are redefining healthcare and creating “unprecedented opportunities for innovation, investment, and impact.” The language reflects partnership rather than transaction, a signal that India is moving from market opportunity to strategic collaboration.

Digital Infrastructure, BIOAsia and the Multinational Innovation Imperative

India’s digital transformation may be its most potent catalyst for long-term health innovation. Unlike many mature systems, the country is building a national-scale digital health infrastructure designed to connect patients, providers, and health systems across a population of more than 1.4 billion people, with a rising middle class of 400 million.

The Global Digital Health Market is projected to grow from USD 288.55 billion in 2024 to USD 2,688 billion by 2035, expanding at a CAGR of 22.55% during 2025–2035. This surge is driven by the rapid adoption of AI-powered diagnostics, telemedicine, wearable devices, and data analytics solutions that are revolutionizing patient care and operational efficiency worldwide.

Hundreds of millions of citizens are already using digital health services, including telemedicine, electronic prescriptions, and remote care. The Ayushman Bharat Digital Mission is creating an interoperable national health ecosystem, enabling secure health records, improved care coordination, and population-scale data infrastructure that supports research, real-world evidence, and precision health.

For multinational companies, this digital backbone creates a uniquely strategic environment, enabling large-scale clinical research, faster pharmacovigilance, AI-supported health insights, and rapid deployment of innovation across diverse populations. India’s digital infrastructure is not simply modernizing health delivery. It is enabling national-scale transformation.

BIOAsia sits at the center of this conversation and convergence. The gathering reflects India’s ambition to lead at the intersection of biology, artificial intelligence, and scalable innovation. Leaders from industry, government, and science convene not only to discuss growth but to shape the next phase of global life sciences, where biology, data, and digital systems converge to influence global health.

One conference panel, among the many high-powered sessions, brings together global leaders in advanced therapeutics to explore how next-generation modalities are moving from discovery to scalable care. Panelists across biopharma, translational science, and hospital systems are examining progress in cell and gene therapies, mRNA, and radiopharmaceuticals, underscoring that innovation now depends as much on manufacturable scale and delivery as on scientific breakthrough. India’s expanding capabilities in clinical research and bioprocessing strengthen its role as a key partner in advancing next-generation therapies.

For multinational innovators, the implications are clear. Engagement in India now extends beyond commercialization. It calls for collaboration in research, investment in digital and scientific ecosystems, alignment with national health priorities and partnership in strengthening health delivery.

India’s Strategic Role in Global Health Innovation

India’s rise in global health innovation reflects the alignment of policy, market growth, digital infrastructure, and scientific capability forces that together are reshaping where and how healthcare innovation occurs.

For multinational companies, India now represents a full-spectrum innovation environment. It is a place to conduct clinical research across diverse populations, scale manufacturing and supply chains, deploy digital health at a national scale, and co-develop solutions addressing both local and global health challenges. Increasingly, India is not simply a recipient of innovation developed elsewhere. It is becoming a co-creator of next-generation health.

This shift changes the strategic equation. Market entry alone is no longer sufficient. Meaningful engagement requires partnership with policymakers, regulators, scientists, health providers, and digital health ecosystems. Organizations that invest in collaboration, align with national health priorities, and contribute to strengthening healthcare systems are most likely to succeed in India’s evolving landscape.

BIOAsia sets the stage for this transformation. It is more than a conference. It is a convergence of global health ambition, scientific capability, and policy momentum. The conversations taking place in Hyderabad mirror a broader reality: the geography of health innovation is expanding, and India is now central to its future.

For global health innovators, the question is no longer whether India matters. The question is how deeply they choose to engage in shaping what comes next.

The post India: The Growing Focal Point for Health Innovation appeared first on Medika Life.

Many private-sector investors are considering health in Africa. Maybe that’s no surprise; the African Development Bank says the Continent could almost double its GDP if health were better. Robert Appelbaum, though, thinks that many are interested in what Africa might export as well as the potential unlocked at home.

Appelbaum has advised multinational pharma companies through the most difficult episodes of the past three decades including the disputes over HIV medicines patents and the transfer of technology to African producers. He also provides legal and business counsel to billionaires who are household names. “Today, investors are looking at the African Continental Trade Agreement (AFCTA) and the commercialisation of African drugs and devices for use across the world,” he told me. “The AFCTA is making Africa into a legitimate manufacturing hub for the full gamut of manufacture from API [active pharmaceutical ingredients] through to fill and finish, whereas in the past we have been in the business of fill and finish,” he added.

The day before we spoke I had been to see the Biomedical Research Institute at Stellenbosch. It houses a network of 26 BSL-3 — highly secure — laboratories to handle infectious diseases samples. There are probably a third as many BSL-3 labs at Stellenbosch alone as there in all of China. The Biobank in the same facility has space for up to seven million samples and provides an exceptionally rapid way of looking back at the evolution of disease outbreaks. It was designed to allow another seven million to be stored when needed. To give an idea of how massive this is, the largest biobank in China can hold 10 million samples and the largest human biobank in Europe can keep 20 million. Maybe the most impressive statistic is that the Stellenbosch institute was completed for about €65 million, a fraction of what it would have cost in Europe.

Cost is not Africa’s only advantage: it has the kind of frugal innovation that hard-pressed European and American health systems need. “There is a huge amount of work taking place — more in devices and technology than in drug discovery. Africans are very innovative at creating for ourselves what does not already exist,” Appelbaum said. These are exactly the areas in which slow first-world innovation is holding back medicine: commissions on antimicrobial resistance assumed point-of-care diagnostics would by now have been able to differentiate between viral and bacterial illnesses and between different kinds of infectious bacteria. They cannot.

Pre-history gives Africa another advantage. As humans spread across the globe from Africa, we lost genetic diversity. It’s said that today there is more genetic diversity within Mozambique than between people in South Asia and people in Europe. In that vast genetic storehouse are hidden undiscovered clues to resisting and treating disease — clues that can be transformed into prevention, diagnosis and treatment by health innovators. As Africans have more access to health services, those genetic assets and liabilities will become more and more evident and accessible. This is a key aspect of the African Human Genome project and of South African agreements with commercial entities such as Illumina and MGI.

To spot the real life implications of these genetic patterns, to find population clusters and to identify possible genetic outliers, a country needs easy, secure access to massive numbers of records. The United Kingdom sees this as a competitive advantage for its four national health services while France’s La poste, the nation’s post office, is bringing together over 40 million patients’ referrals, visit reports and test results. These and other developed world efforts, though, are having to retrofit national analytical frameworks onto multiple old data systems and to pry data loose from academics and care systems with strong proprietorial instincts. African countries are building new national data systems from the bottom up with integration and analysis as part of the original design. Appelbaum thinks that Africa may again leapfrog over Western competitors, just as it did by introducing modern mobile telephony and mobile payment systems while legacy system owners slowed down adoption in Europe and the Americas.

Many think that Oracle has already honed in on the opportunity. It has partnered with the Tony Blair Institute to introduce vaccine tracking systems in Ghana, Rwanda and Sierra Leone and to promote them Continent-wide. Given the vast effort that Oracle continues to put into developing a nationwide repository of health records in the USA and the Gulf states, many see its efforts in Africa as a test run for much broader and more ambitious national health databases. African countries are not waiting. Kenya’s Afya Yangu platform is already operational in a third of the nation’s counties and provides portable individual records including medical history, prescriptions, lab results, and appointments for three million users. South Africa faces some of the same challenges as Europe in unifying or supplanting existing systems but its Health Patient Registration System has registered over 57 million patients across more than 3,000 facilities as a foundation for portable electronic health records. Africa’s health data is a vast opportunity which governments will need to use as the basis for investment.

Private sector health investors are indispensable to Africa, Appelbaum thinks. In the US and Europe, they find far more R&D than governments and foundations combined; that must be the pattern in Africa if the Continent is to not just meet its own health needs but to develop innovations for the world.

The post Why Sophisticated Investors Really Care about Health in Africa appeared first on Medika Life.

In later life, weight loss can be a double‑edged sword. A few pounds off the joints can be both helpful and risky. Shedding a few pounds may ease joint pain, but losing weight without meaning to can be a warning sign. Fast weight loss can also lead to muscle loss, which is key to staying independent.

Experts also point out practical issues: injections need good vision, steady hands, and a regular routine. Stomach and bowel side effects can be tougher for seniors, especially if they’re already losing weight without trying. complicate life for older adults — and how to approach them with a “safety first” mindset.

1) Aging changes the risk–benefit math (even when a drug “works”)

Older adults, especially those who are frail or have several health issues, are often left out of clinical trials. This is important because average trial results may not match the real-life experience of a 75-year-old who takes several medications and needs to manage appetite and hydration.

A 2024 debate paper on GLP-1 drugs in older patients, including those with kidney disease, points out that limited trial data and multiple medications make it harder to judge safety and effectiveness for frailer seniors. Clinicians need to make decisions based on each person, not just on averages. In simple terms, the real question is not whether GLP-1s are good or bad, but whether they help this specific older person with their unique health needs.

There’s another subtle issue: in later life, the goal is often less about chasing an ideal weight and more about protecting function—walking safely, rising from a chair, maintaining balance, staying hydrated, and maintaining enough strength to live independently. So for older adults, the most important question isn’t “How much weight will I lose?” It’s “What will this do to my strength, my nutrition, and my ability to stay steady on my feet?”

2) Common side effects can become serious for older adults.

GLP-1s often cause nausea, vomiting, diarrhea, constipation, and less appetite. Younger people may find these symptoms unpleasant but manageable. For older adults, though, these issues can quickly lead to dehydration, dizziness, and falls, especially if they also take blood pressure medicines or diuretics.

Current FDA labeling for semaglutide products highlights this pathway: stomach and bowel side effects can lead to volume depletion, and acute kidney injury has occurred, including in postmarketing reports. The label advises monitoring kidney function when starting or increasing doses in people who develop severe gastrointestinal reactions, and it notes that dehydration has been part of reported kidney injury cases.

This is how many real-life problems start: a few days of not being able to eat or drink much, then feeling lightheaded, falling, or needing emergency care for dehydration. Older adults may not feel as thirsty and may have less ability to recover. So, it’s important to watch hydration, electrolytes, blood pressure, and kidney function, especially in the first months of treatment and after increasing the dose.

3) Muscle and frailty: losing weight does not always mean better health.

The headline benefits of GLP‑1s often focus on pounds lost. But the body doesn’t lose only fat. Lean mass (including muscle) can drop, too. This matters in older adults because age‑related muscle loss (sarcopenia) is already common — and it’s tightly linked to frailty, falls, and loss of independence.

A 2025 mini-review on older adults warns that starting and stopping GLP-1s repeatedly can change body composition, sometimes leading to ‘sarcopenic obesity’ — having too much fat and too little muscle. The authors are not saying to avoid GLP-1s, but to remember that weight loss does not always mean better health for older people.

More pointedly, a 24‑month retrospective cohort study in older adults with type 2 diabetes reported that semaglutide use was associated with muscle loss and functional decline, particularly at higher doses and in patients who already had sarcopenia. The authors emphasize individualized risk–benefit assessment and the need for monitoring and intervention.

If you’re reading this as an older adult, it may help to translate the research into plain questions to bring to your next appointment: “If I lose weight, how will we protect my muscles?” “How will we check whether I’m getting weaker?” “What would make us stop or change course?” An older adult who becomes “smaller but weaker” has not gained health — only risk.

4) Other complications: gallbladder, pancreas, vision, and low blood sugar

Gallbladder and bile duct problems can be an unexpected issue. Losing weight already increases the risk of gallstones, and GLP-1s seem to increase it even further. A large review found that using GLP-1 drugs increases the chance of gallbladder or bile duct disease, especially at higher doses, for longer periods, or when used for weight loss.

For older adults, this might present as sudden pain in the upper right side of the belly, nausea, fever, or pain spreading to the back or shoulder. These symptoms should be checked by a physician right away.

GLP-1 drug labels also warn about the risk of sudden pancreatitis and say to get medical help for severe, ongoing belly pain. The overall risk is low, but older adults may have additional risk factors, such as gallstones or high triglycerides. Severe belly pain in later life should always be checked quickly.

Then there’s the risk of blood sugar dropping too low. GLP‑1s don’t usually cause hypoglycemia by themselves, but the risk rises when combined with insulin or sulfonylureas. Semaglutide labeling warns that concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia and may require dose reductions of those agents.

In older adults, hypoglycemia can be particularly dangerous: it can cause falls, confusion, fainting, and cardiac stress. It’s also easier to miss, because symptoms may look like “just being tired” or “a little off today,” especially in someone who already has memory or balance problems.

Eyes and vision deserve special attention. Semaglutide labeling includes a warning about diabetic retinopathy complications and recommends monitoring patients with a history of retinopathy. Beyond labeling, post‑marketing safety monitoring continues to explore visual signals.

A 2025 analysis of FDA adverse event reporting data found a potentially elevated risk of vision‑impairment reports with semaglutide use compared with some other diabetes and weight‑loss medications, and it called for vigilant surveillance and further research. That doesn’t prove the drug causes vision loss in an individual patient, but it is enough to justify a cautious posture: new blurring, blind spots, or sudden changes deserve a same‑week medical call, not a “let’s see if it passes.”

5) Surgery and sedation: delayed stomach emptying can cause problems

GLP‑1 medications slow stomach emptying — one reason people feel full sooner. But that same effect can complicate anesthesia and deep sedation if food remains in the stomach despite standard fasting. A 2024 review describes the connection between GLP‑1 medications, delayed gastric emptying (including gastroparesis), and increased risk of aspiration during anesthesia, as well as possible effects on the absorption of other medications.

This issue has become important enough that several medical groups have created guidelines for surgery. The 2024 guidance says many people can continue taking GLP-1s, but doctors should look for higher-risk situations, such as people with stomach problems or other risks of food entering the lungs, and adjust plans as needed.

This is important for older adults because they are more likely to undergo procedures requiring sedation, such as colonoscopies, joint injections, cardiac procedures, dental work, or surgeries. The easiest and most often missed safety step is to tell every physician involved — surgeon, anesthesiologist, endoscopist, dentist — that you are taking a GLP-1 medication and when you last took it. Do not assume it will be clear in your medical chart.

6) A senior‑friendly “yes, with a plan” approach

If you’re an older adult considering a GLP‑1 (or already taking one), a safer approach often looks like “yes, with monitoring.” That means starting with function, not just the scale: tracking energy, steadiness, and strength in everyday life, not only pounds.

It also means treating hydration as a real medical concern. Ongoing nausea, vomiting, or diarrhea is not just part of getting used to the medicine. These symptoms can affect blood pressure and kidney function, especially when changing doses.

Because muscle matters so much in later life, protecting it should be part of the prescription. That can include discussing protein intake, adding a realistic strength plan (even chair‑based work or physical‑therapy guided resistance), and reassessing the medication if weight loss is accompanied by weakness, poor balance, or reduced stamina.

Older adults should also have their medications reviewed with a focus on preventing low blood sugar. If insulin or a sulfonylurea is being used, doses may need to be adjusted as appetite decreases and blood sugar improves.

Finally, it is important to take symptoms seriously. New stomach pain, ongoing vomiting, or sudden vision changes should be checked by a doctor right away. Before any procedure with anesthesia or deep sedation, make sure to tell the medical team about your GLP-1 use — do not assume they already know.

The GLP-1 medications can help some older adults, but there is less room for mistakes. Side effects can quickly lead to dehydration, frailty, falls, or problems during procedures. The safest approach is not just ‘yes’ or ‘no,’ but ‘yes, with a plan’ — one that protects hydration, nutrition, muscle, vision, and safety during medical care.

The post GLP‑1 Medications in Later Life: Why the “Miracle Shot” Needs a Senior‑Specific Safety Lens appeared first on Medika Life.

Healthcare is no exception, and in the wake of the murder of George Floyd and the national awakening to the scourge of systemic racism in our country, more and more conversations about racism in healthcare are being had, across our country, and in the medical literature. This is only a good thing, and I hope and pray they lead to rectification of the healthcare disparities faced by people of color in this country.

One such conversation was recorded in the excellent Critical Matters podcast, hosted by Dr. Sergio Zanotti — world-renown Critical Care Medicine specialist and Chief Medical Officer for Sound Critical Care, a national critical care medicine practice. He was speaking with Dr. Greg Johnson, Sound Physicians’ Chief Medical Officer for Hospital Medicine and thought leader within his field and a champion for diversity, inclusion, and belonging within medicine.

In this episode, Dr. Zanotti and Dr. Johnson have an honest conversation about healthcare, race, and racism in healthcare. It was eye-opening, and it is a must-listen for every healthcare professional in this country. You can listen to it here:

Dr. Johnson reiterated that many Black Americans must go to great lengths to let members of the healthcare team taking care of their families know the value of their loved one: what job they do; what they mean to their families; what they mean their communities.

First of all, I was shocked by this. And yet, when I thought back to my Black patients and their families, I realized that many of them did just that: go out of their way to let me know how important this patient in front of us was to them, their family, and their community.

Just the other day, I had a husband tell me, “This woman, she is the rock of our family.” Another family member of a patient with COVID-19 told me something similar. I never paid attention to this phenomenon, and I am so very grateful I heard this conversation to open my eyes to this reality.

This is wrong. This is horrific. This is terribly sad. No one should have to justify to me why their loved one is important, how prominent their loved one is in the community. It is absolutely horrible that Dr. Tyson’s had to show the healthcare professionals taking of his father that his father was a prominent lecturer in order to garner respect from them. How can this be?

Every patient we take care of has worth, has value. Black, Brown, Yellow, Red, or White, all our patients have worth, and the fact that Black Americans feel the need to describe how important their loved ones are to get respect is truly nauseating. And you know what they are saying to us? Black Lives Matter.

Painful though it may be, it is reality, and it is of absolute importance that we in healthcare are cognizant of this reality and work to rectify it. Indeed, I told that husband that his wife has worth, and I will do all that I can to care for her within her values and wishes.

Racism in healthcare is real; it is pervasive; it is indeed a pandemic. We need to acknowledge it and then work to overcome it. All of us in healthcare have a responsibility to do what we can to achieve this end. And for starters, all of us in healthcare should listen to this conversation about racism in healthcare to understand the problem and how to fix it.

The post Every Healthcare Professional Must Listen To This Conversation appeared first on Medika Life.

Lydia Romero strained to hear her husband’s feeble voice through the phone.

A week earlier, immigration agents had grabbed Julio César Peña from his front yard in Glendale, California. Now, he was in a hospital after suffering a ministroke. He was shackled to the bed by his hand and foot, he told Romero, and agents were in the room, listening to the call. He was scared he would die and wanted his wife there.

“What hospital are you at?” Romero asked.

“I can’t tell you,” he replied.

Viridiana Chabolla, Peña’s attorney, couldn’t get an answer to that question, either. Peña’s deportation officer and the medical contractor at the Adelanto ICE Processing Center refused to tell her. Exasperated, she tried calling a nearby hospital, Providence St. Mary Medical Center.

“They said even if they had a person in ICE custody under their care, they wouldn’t be able to confirm whether he’s there or not, that only ICE can give me the information,” Chabolla said. The hospital confirmed this policy to KFF Health News.

Family members and attorneys for patients hospitalized after being detained by federal immigration officials said they are facing extreme difficulty trying to locate patients, get information about their well-being, and provide them emotional and legal support. They say many hospitals refuse to provide information or allow contact with these patients. Instead, hospitals allow immigration officers to call the shots on how much — if any — contact is allowed, which can deprive patients of their constitutional right to seek legal advice and leave them vulnerable to abuse, attorneys said.

Hospitals say they are trying to protect the safety and privacy of patients, staff, and law enforcement officials, even while hospital employees in Los Angeles, Minneapolis, and Portland, Ore., cities where Immigration and Customs Enforcement has conducted immigration raids, say it’s made their jobs difficult. Hospitals have used what are sometimes called blackout procedures, which can include registering a patient under a pseudonym, removing their name from the hospital directory, or prohibiting staff from even confirming that a patient is in the hospital.

“We’ve heard incidences of this blackout process being used at multiple hospitals across the state, and it’s very concerning,” said Shiu-Ming Cheer, the deputy director of immigrant and racial justice at the California Immigrant Policy Center, an advocacy group.

Some Democratic-led states, including California, Colorado, and Maryland, have enacted legislation that seeks to protect patients from immigration enforcement in hospitals. However, those policies do not address protections for people already in ICE custody.

More Detainees Hospitalized

Peña is among more than 350,000 people arrested by federal immigration authorities since President Donald Trump returned to the White House. As arrests and detentions have climbed, so too have reports of people taken to hospitals by immigration agents because of illness or injury — due to preexisting conditions or problems stemming from their arrest or detention.

ICE has faced criticism for using aggressive and deadly tactics, as well as for reports of mistreatment and inadequate medical care at its facilities. Sen. Adam Schiff (D-Calif.) told reporters at a Jan. 20 news conference outside a detention center he visited in California City that he spoke to a diabetic woman held there who had not received treatment in two months.

While there are no publicly available statistics on the number of people sick or injured in ICE detention, the agency’s news releases point to 32 people who died in immigration custody in 2025. Six more have died this year.

The Department of Homeland Security, which oversees ICE, did not respond to a request for information about its policies or Peña’s case.

According to ICE’s guidelines, people in custody should be given access to a telephone, visits from family and friends, and private consultation with legal counsel. The agency can make administrative decisions, including about visitation, when a patient is in the hospital, but should defer to hospital policies on contacting next of kin when a patient is seriously ill, the guidelines state.

Asked in detail about hospital practices related to patients in immigration custody and whether there are best practices that hospitals should follow, Ben Teicher, a spokesperson for the American Hospital Association, declined to comment.

David Simon, a spokesperson for the California Hospital Association, said that “there are times when hospitals will — at the request of law enforcement — maintain confidentiality of patients’ names and other identifying characteristics.”

Although policies vary, members of the public can typically call a hospital and ask for a patient by name to find out whether they’re there, and often be transferred to the patient’s room, said William Weber, an emergency physician in Minneapolis and medical director for the Medical Justice Alliance, which advocates for the medical needs of people in law enforcement custody. Family members and others authorized by the patient can visit. And medical staff routinely call relatives to let them know a loved one is in the hospital, or to ask for information that could help with their care.

But when a patient is in law enforcement custody, hospitals frequently agree to restrict this kind of information sharing and access, Weber said. The rationale is that these measures prevent unauthorized outsiders from threatening the patient or law enforcement personnel, given that hospitals lack the security infrastructure of a prison or detention center. High-profile patients such as celebrities sometimes also request this type of protection.

Several attorneys and health care providers questioned the need for such restrictions. Immigration detention is civil, not criminal, detention. The Trump administration says it’s focused on arresting and deporting criminals, yet most of those arrested have no criminal conviction, according to data compiled by the Transactional Records Access Clearinghouse and several news outlets.

Taken Outside His Home

According to Peña’s wife, Romero, he has no criminal record. Peña came to the United States from Mexico in sixth grade and has an adult son in the U.S. military. The 43-year-old has terminal kidney disease and survived a heart attack in November. He has trouble walking and is partially blind, his wife said. He was detained Dec. 8 while resting outside after coming home from dialysis treatment.

Initially, Romero was able to find her husband through the ICE Online Detainee Locator System. She visited him at a temporary holding facility in downtown Los Angeles, bringing him his medicines and a sweater. She then saw he’d been moved to the Adelanto detention center. But the locator did not show where he was after he was hospitalized.

When she and other relatives drove to the detention facility to find him, they were turned away, she said. Romero received occasional calls from her husband in the hospital but said they were less than 10 minutes long and took place under ICE surveillance. She wanted to know where he was so she could be at the hospital to hold his hand, make sure he was well cared for, and encourage him to stay strong, she said.

Shackling him and preventing him from seeing his family was unfair and unnecessary, she said.

“He’s weak,” Romero said. “It’s not like he’s going to run away.”

ICE guidelines say contact and visits from family and friends should be allowed “within security and operational constraints.” Detainees have a constitutional right to speak confidentially with an attorney. Weber said immigration authorities should tell attorneys where their clients are and allow them to talk in person or use an unmonitored phone line.

Hospitals, though, fall into a gray area on enforcing these rights, since they are primarily focused on treating medical needs, Weber said. Still, he added, hospitals should ensure their policies align with the law.

Family Denied Access

Numerous immigration attorneys have spent weeks trying to locate clients detained by ICE, with their efforts sometimes thwarted by hospitals.

Nicolas Thompson-Lleras, a Los Angeles attorney who counsels immigrants facing deportation, said two of his clients were registered under aliases at different hospitals in Los Angeles County last year. Initially, the hospitals denied the clients were there and refused to let Thompson-Lleras meet with them, he said. Family members were also denied access, he said.

One of his clients was Bayron Rovidio Marin, a car wash worker injured during a raid in August. Immigration agents surveilled him for over a month at Harbor-UCLA Medical Center, a county-run facility, without charging him.

In November, the Los Angeles County Board of Supervisors voted to curb the use of blackout policies for patients under civil immigration custody at county-run hospitals. In a statement, Arun Patel, the chief patient safety and clinical risk management officer for the Los Angeles County Department of Health Services, said the policies are designed to reduce safety risks for patients, doctors, nurses, and custody officers.

“In some situations, there may be concerns about threats to the patient, attempts to interfere with medical care, unauthorized visitors, or the introduction of contraband,” Patel said. “Our goal is not to restrict care but to allow care to happen safely and without disruption.”

Leaving Patients Vulnerable

Thompson-Lleras said he’s concerned that hospitals are cooperating with federal immigration authorities at the expense of patients and their families and leaving patients vulnerable to abuse.

“It allows people to be treated suboptimally,” Thompson-Lleras said. “It allows people to be treated on abbreviated timelines, without supervision, without family intervention or advocacy. These people are alone, disoriented, being interrogated, at least in Bayron’s case, under pain and influence of medication.”

Such incidents are alarming to hospital workers. In Los Angeles, two health care professionals who asked not to be identified by KFF Health News, out of concern for their livelihoods, said that ICE and hospital administrators, at public and private hospitals, frequently block staff from contacting family members for people in custody, even to find out about their health conditions or what medications they’re on. That violates medical ethics, they said.

Blackout procedures are another concern.

“They help facilitate, whether intentionally or not, the disappearance of patients,” said one worker, a physician for the county’s Department of Health Services and part of a coalition of concerned health workers from across the region.

At Legacy Emanuel Medical Center in Portland, nurses publicly expressed outrage over what they saw as hospital cooperation with ICE and the flouting of patient rights. Legacy Health has sent a cease and desist letter to the nurses’ union, accusing it of making “false or misleading statements.”

“I was really disgusted,” said Blaire Glennon, a nurse who quit her job at the hospital in December. She said numerous patients were brought to the hospital by ICE with serious injuries they sustained while being detained. “I felt like Legacy was doing massive human rights violations.”

Handcuffed While Unconscious

Two days before Christmas, Chabolla, Peña’s attorney, received a call from ICE with the answer she and Romero had been waiting for. Peña was at Victor Valley Global Medical Center, about 10 miles from Adelanto, and about to be released.

Excited, Romero and her family made the two-hour-plus drive from Glendale to the hospital to take him home.

When they got there, they found Peña intubated and unconscious, his arm and leg still handcuffed to the hospital bed. He’d had a severe seizure on Dec. 20, but no one had told his family or legal team, his attorney said.

Tim Lineberger, a spokesperson for Victor Valley Global Medical Center’s parent company, KPC Health, said he could not comment on specific patient cases, because of privacy protections. He said the hospital’s policies on patient information disclosure comply with state and federal law.

Peña was finally cleared to go home on Jan. 5. No court date has been set, and his family is filing a petition to adjust his legal status based on his son’s military service. For now, he still faces deportation proceedings.

The post ‘I Can’t Tell You’: Attorneys, Relatives Struggle To Find Hospitalized ICE Detainees appeared first on Medika Life.

We usually think about outdoor air quality, but sometimes the air in our kitchens is even more dangerous. Did you ever think that home cooking could be dangerous for you? Not in terms of spills or burns, but the air you breathe?

Understanding the Problem

People in the UK spend about 90% of their time indoors, but most air pollution rules only focus on outdoor air. This is a serious problem because many things we do at home, especially cooking, create airborne pollutants that can harm our health.

The INGENIOUS project at the University of York is studying what happens to indoor air quality when we cook. Their research examines homes where many families experience poor air quality both indoors and outdoors.

What’s in the Air When You Cook?

Cooking releases several types of pollutants into your home’s air. The main ones are fine particulate matter (PM2.5), nitrogen dioxide, volatile organic compounds, and formaldehyde. Did you ever think you would be breathing formaldehyde in your home as a result of how you cooked?

PM2.5 is especially concerning. These tiny particles can travel deep into your lungs and even get into your bloodstream. One study found that pan-frying chicken produced PM2.5 levels of 92.9 micrograms per cubic meter. The outdoor air quality standard for PM2.5 is 50 micrograms per cubic meter, so some cooking methods can more than double that amount in your kitchen.

Gas stoves create another issue. They release nitrogen dioxide (NO2), which can irritate your lungs and is linked to asthma and other breathing problems. If you don’t use a range hood, cooking with gas can add 25% to 33% more nitrogen dioxide to your indoor air in summer, and even more in winter. In four out of ten homes studied, gas burners released enough nitrogen dioxide to go over the health standards set for outdoor air.

Who’s Most at Risk?

Young children, older adults, and people with asthma or heart and lung diseases are especially at risk.

The numbers are worrying for children with asthma. A 2006 study found that pollution from gas stoves more than doubles the chances of wheezing and shortness of breath for kids with asthma who live in apartments. Another study showed that children with asthma who are exposed to higher nitrogen dioxide levels use their rescue inhalers 14% more often.

Some communities are affected more than others. In Washington State, Black people are exposed to PM2.5 levels that are over 1.3 times higher than White people, and Asian people face levels 1.5 times higher. American Indian and Alaska Native adults have the highest asthma rates at 18%. And there are cultural factors at work here, as well as the type of cooking you do indoors and the airflow in your home.

The Long-Term Health Impact

Being exposed to PM2.5 for a long time raises the risk of early death for people with heart or lung disease. It is also linked to chronic heart and lung problems, effects on brain health, and pregnancy issues.

Around the world, household air pollution causes 6.7 million early deaths each year. The main health problems are stroke, heart disease, chronic obstructive pulmonary disease (COPD), and lung cancer.

Use Your Range Hood Every Time You Cook

This is the most important step you can take. A range hood that works well and vents air outside can remove 50% to 70% of pollutants if you use it correctly. But studies show that people use their range hoods only 36% of the time in houses and 28% in apartments.

If your range hood only recirculates air back into the kitchen instead of venting it outside, you should open windows or use another exhaust fan.

Cook on Your Back Burners

Range hoods work best when you use the back burners because they are more fully covered by the hood. Cooking on a single back burner with the hood on low speed usually captures 50% to 70% of the pollutants.

Open Windows and Doors

If you do not have a range hood, opening windows or doors can help. One study found that opening both the front and back doors for ventilation creates strong airflow that can remove over 95% of cooking pollutants in just 10 minutes.

Consider Switching to Electric

All cooking creates some pollution, but gas stoves cause extra problems by releasing nitrogen dioxide, carbon monoxide, and benzene. A recent Stanford study found that switching to electric stoves could lower nitrogen dioxide exposure by over 50% across the country. One of the problems, of course, is that electricity or cooking with electricity is more expensive than using gas.

Choose Your Cooking Methods Wisely

Pan-frying and stir-frying at high temperatures make much more pollution than boiling, steaming, or using an air fryer. When you can, choose cooking methods that use lower temperatures.

Why This Matters Now

About half of the people surveyed did not know that cooking creates unhealthy air pollutants. But after learning about the health risks, 64% said they would think about using their ventilation devices more often.

People are spending more time at home. In 2021, Americans spent about 62% of their waking hours at home, up from 50% in 2019. With more people cooking at home, kitchen ventilation is more important.

Newer homes are built to be more energy-efficient, so there is less air exchange with the outdoors. Without good ventilation, pollutants can get trapped inside and build up to harmful levels. In homes with poor ventilation, indoor smoke can have fine particle levels 100 times higher than what is considered safe.

The Bottom Line

Cooking is a normal part of daily life, but it shouldn’t harm your health. By learning what pollutants are released when you cook and taking simple steps to ventilate your kitchen, you can protect yourself and your family.

The research is clear: using a range hood every time you cook, opening windows for airflow, cooking on back burners, and thinking about cleaner cooking technologies can really help. These are not complicated or expensive changes. They are simple habits that can greatly improve the air quality in your home and your health as well.

The post Home Cooking Means Hidden Health Dangers for You appeared first on Medika Life.

It was the fall of 2022 when large language models and Generative AI burst out of research labs and onto Main Street. Since then, every day seems to bring another AI breakthrough that challenges how work gets done.

In my role advising organizations on AI strategy and deployments, I see a consistent pattern among healthcare leaders: excitement about what AI could unlock, paired with exhaustion from the volume of noise, pressure, and competing claims.

Welcome to 2026.

As predictions flood inboxes and social feeds, focused on what AI might do next, I want to ground the conversation in something more useful. Rather than forecasting outcomes, let’s focus on three forces already at work—forces that will determine whether AI delivers real value in healthcare or quietly stalls.

Will 2026 be a year of boom, bust, or backlash?

The honest answer is yes.

Boom: Early Wins—and an AI Arms Race

Let’s start with what’s working.

Healthcare is seeing real, if narrow, gains from AI:

• Ambient documentation reduces administrative burden
• Imaging and pathology tools iare mproving speed and consistency
• Operational and revenue cycle applications driving incremental efficiency

These are not moonshots. They are targeted solutions addressing specific pain points. And they matter.

At the same time, healthcare is now firmly in an AI arms race.

Every EHR vendor, medical device company, life sciences firm, and digital health startup is racing to declare itself “AI-native.” Roadmaps are packed with copilots, assistants, agents, and automation claims. No vendor wants to be perceived as falling behind.

That pressure is accelerating innovation—but it’s also compressing timelines, encouraging over-promising, and pushing organizations to adopt faster than they can realistically absorb.

Boom energy is real.

But it is also uneven and fragile.

Prediction: Within two years, most AI used in provider organizations will arrive embedded inside core systems and devices already in use. Intelligence will not be something teams “add on”; it will be something they inherit.

Recommendation: Understand where AI is already embedded across your vendor ecosystem and what’s coming next. Engage early through advisory councils or pilots. Engage and prepare clinicians before introducing these capabilities into workflows. AI should never arrive as a surprise.

Bust: When Pilots Multiply, but Value Doesn’t

Generative AI has dominated innovation agendas, yet only a fraction of pilots ever reach sustained production. A survey cited by MIT reports that roughly 95% of business AI pilots fail to generate measurable returns.

This is not evidence that AI lacks value.

It is evident that many organizations lack discipline.

High failure rates are normal in early markets. Technology matures. Tools improve. But value only materializes when leaders focus on fundamentals: design, data readiness, workflow integration, and ownership.

Most AI initiatives fail not because the technology doesn’t work, but because success is never clearly defined. Projects are launched out of curiosity, vendor pressure, or fear of being left behind. Clinical impact, operational accountability, and economic value are clarified too late—if at all.

Equally damaging is the underestimation of the human systems AI enters. Healthcare work is relational, regulated, and trust-dependent. When AI is introduced without redesigning workflows, preparing staff, or clarifying responsibility, it creates friction—not relief. Adoption then stalls quietly.

Prediction: In 2026, organizations will run fewer AI pilots—but with much higher expectations. Boards and executives will require clearer evidence of clinical, workforce, or financial value before approving new initiatives.

Recommendation: Move from “fail fast” to “fail before you scale.” Define success upfront, assign ownership early, and redesign workflows in tandem with technology. AI initiatives without a credible path to value should be halted immediately.

Backlash: Fear, Workforce Anxiety, and the Trust Gap

The most underestimated force shaping AI’s trajectory in 2026 is neither technical nor financial.

It’s human.

History offers context. When automobiles first appeared, they were seen as dangerous and socially disruptive. Red Flag laws required people to walk ahead of vehicles waving flags and capped speeds at just a few miles per hour. These laws weren’t about innovation—they were about fear, control, and adjustment.

Healthcare AI is entering a similar phase.

Workforce research shows healthcare workers are among the most cautious about AI adoption, citing concerns about trust, transparency, and job impact. This caution is not irrational. Healthcare has a long history of technology being imposed rather than co-designed.

As a result, scrutiny is increasing—particularly from labor organizations and state legislators. Recent bills, including those limiting AI’s role in clinical decision-making and licensed practice, reflect not anti-innovation sentiment, but unresolved trust and knowledge gaps.

Innovation does not scale without trust.

In 2026, AI scrutiny will intensify, especially with labor organizations and at the state legislative level.

As I write this, the Chair of the New York State Senate Committee on Internet and Technology just introduced a bill (S7263) to “protect patients and front-line care workers from the adverse effects of AI tools in risky or untested settings.”  The bill prohibits chatbots from performing the duties of licensed nurses and puts strong guardrails around the use of AI in healthcare settings.”

I often write about the need for a balanced approach to defining both the “gas and guardrails” that guide AI’s use in health and medicine. Incentives and safeguards are equally important.

Prediction: Expect increased legislative activity and labor engagement around AI in healthcare throughout 2026. Such actions should not be dismissed simply as anti-innovation. They reflect something deeper: a trust and knowledge gap that needs to be closed.

Recommendation: Create durable AI value by investing in workforce and consumer education. Clinicians need clarity—not just on how AI works, but on how it supports professional judgment rather than replaces it.

From Awe to Analytical

The year ahead will test the resolve of leadership. Transformation in healthcare is rarely linear—and never clean.

Vendors will continue to showcase breakthroughs. The hype will continue. But 2026 is not the year for cheerleading.

It is the year for realism.

The most effective leaders are moving from awe to analysis—recognizing that AI value does not come from the technology itself, but from the opportunity it creates to rethink how work gets done.

In that sense, AI value is—and always will be—a uniquely human process.

The post AI in 2026 – Boom, Bust or Backlash in Healthcare? appeared first on Medika Life.

The health system in India will undergo a seismic shift due to the recent GST reforms. A sector that will see a significant impact is medical tourism, a crucial component of this sector. Unlike the past, when only a select few could afford to travel to other countries for medical treatment, the trend is changing today. According to the Medical Tourism Index, India ranks 10^th among the most sought-after destinations for medical treatment.[1]

The medical tourism sector in India is valued at $8.71 billion and is projected to reach nearly $16 billion by 2030, with a compound annual growth rate of 13.23%.[2] In 2023 alone, 635,000 foreign nationals came to the country seeking medical care.[3] While cost remains a massive draw, the true revolution lies in the holistic and value-driven ecosystem that the country has built. The country is not just offering an affordable alternative. It is redefining what “care beyond borders” means.

Why India is a popular destination

The country’s rise to becoming a global healthcare hub is due to several factors, such as:

• Cutting-edge facilities: There are several outdated notions regarding infrastructure and expertise in healthcare facilities in developing countries. India is proving these assumptions wrong. The country is home to a rapidly growing number of hospitals with state-of-the-art infrastructure, on par with some in the West. Healthcare facilities in several cities, including Delhi, Mumbai, Chennai, and Bengaluru, are equipped with cutting-edge technology and offer a comprehensive range of treatments in several areas such as cardiology, oncology, neurology, fertility treatments, and cosmetic surgery. Many of these institutions have received globally recognized accreditations from the Joint Commission International (JCI)[4] and the National Accreditation Board for Hospitals & Healthcare Providers (NABH), which serve as benchmarks of quality and safety.
• World-class expertise: At the heart of this transformation is the country’s intellectual capital. India has a vast pool of highly skilled medical professionals, many of whom have trained or practiced in prestigious institutions abroad. This creates a unique blend of international expertise with a deeply ingrained ethos of empathetic care.
• Favourable policies: The government has taken a keen interest in medical tourism and has created favourable schemes and initiatives. Some of these include the National Strategy and Roadmap for Medical and Wellness Tourism, a Medical and Wellness Tourism Board, overseas marketing, and e-medical visas. Similarly, the Heal in India initiative aims to highlight both modern and ancient healthcare on a digital platform, offering comprehensive support to those seeking care. Such positive steps have made it easier for medical tourists to access healthcare in the country.  
• Holistic care: Medical tourism is not limited to modern medicine. Tourists flock to the country every year to try out traditional healing systems such as Ayurveda and Yoga. This unique approach to wellness offers a comprehensive path to recovery, addressing the physical ailment and the patient’s mental and spiritual well-being.
• More than affordable care: Cost is an important aspect that draws scores of people, but India’s healthcare system is more than a medical bill. It includes a seamless patient experience, often managed by dedicated “medical value travel facilitators.” These services handle everything from visa assistance and travel arrangements to language interpretation and post-operative follow-up. Minimal waiting time is another critical factor, which can be a life-saving advantage in time-sensitive cases.
• Overcoming language barriers: An overlooked but practical advantage in India is the widespread use of English. Most doctors, nurses, and hospital staffers in major medical institutions speak in English, which makes communication easy and builds trust with international patients. This ease of interaction is a crucial factor when patients are making a decision about therapy, as it reduces anxiety and provides clarity about the treatment plan.

Navigating challenges and leveraging opportunities

Despite its position, the medical tourism sector faces several challenges. While government initiatives are yielding results, some systemic issues still need to be addressed. Simplifying the visa process, ensuring consistent quality across all tiers of hospitals, and building a stronger regulatory framework to protect patients are all vital steps for sustained growth.

At the same time, there are immense opportunities for growth. The rise in digital healthcare tools, such as telemedicine, is making cross-border consultations and follow-ups easier, bridging the geographical gap and building trust even before a patient leaves their home. The country’s strategic focus on attracting patients from a wider range of countries, which includes developed nations, by highlighting its comprehensive care model, will be key to helping this sector flourish.

Medical Tourism 2.0 may seem like a market trend, but it is redefining what healthcare can be. India, with its high-tech hospitals, skilled professionals, and a rich legacy of holistic wellness, is no longer a mere participant in this market. It is a catalyst for systemic change. The country’s commitment to patient-centric care is creating a model where healing is no longer limited by geography. The country is confidently positioning itself as a destination for treatment and a sanctuary for healing, proving that in the future, “care beyond borders” will be the new global standard.

[1] https://www.medicaltourism.com/destinations/india

[2] https://www.mordorintelligence.com/industry-reports/india-medical-tourism-market

[3] https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2036816

[4] https://www.jointcommission.org/en/about-us/recognizing-excellence/find-accredited-international-organizations?rfkid_7:content_filters=country:eq:India&rfkid_7:content_page=1&rfkid_7:content_limit=100

The post Care Beyond Borders: India Redefining the Future of Medical Tourism appeared first on Medika Life.

Last winter, Amber Wingler started getting a series of increasingly urgent messages from the local hospital in Columbia, Missouri, letting her know her family’s health care might soon be upended.

MU Health Care, where most of her family’s doctors work, was mired in a contract dispute with Wingler’s health insurer, Anthem. The existing contract was set to expire.

Then, on March 31, Wingler received an email alerting her that the next day Anthem was dropping the hospital from its network. It left her reeling.

“I know that they go through contract negotiations all the time … but it just seemed like bureaucracy that wasn’t going to affect us. I’d never been pushed out-of-network like that before,” she said.  

The timing was awful.

The query: When a Missouri mom’s health insurance company couldn’t come to an agreement with her hospital, most of her doctors were suddenly out-of-network. She wondered how she would get her kids’ care covered or find new doctors. “For a family of five, … where do we even start?”

— Amber Wingler, 42, in Columbia, Missouri

Wingler’s 8-year-old daughter, Cora, had been having unexplained troubles with her gut. Waitlists to see various pediatric specialists to get a diagnosis, from gastroenterology to occupational therapy, were long — ranging from weeks to more than a year.

(In a statement, MU Health Care spokesperson Eric Maze said the health system works to make sure children with the most urgent needs are seen as quickly as possible.)

Suddenly, the specialist visits for Cora were out-of-network. At a few hundred bucks a piece, the out-of-pocket cost would have added up fast. The only other in-network pediatric specialists Wingler found were in St. Louis and Kansas City, both more than 120 miles away.

So Wingler delayed her daughter’s appointments for months while she tried to figure out what to do.

Nationwide, contract disputes are common, with more than 650 hospitals having public spats with an insurer since 2021. They could become even more common as hospitals brace for about $1 trillion in cuts to federal health care spending prescribed by President Donald Trump’s signature legislation signed into law in July.

Patients caught in a contract dispute have few good options. “There’s that old African proverb: that when two elephants fight, the grass gets trampled. And unfortunately, in these situations, oftentimes patients are grass,” said Caitlin Donovan, a senior director at the Patient Advocate Foundation, a nonprofit that helps people who are having trouble accessing health care.

If you’re feeling trampled by a contract dispute between a hospital and your insurer, here is what you need to know to protect yourself financially:

1. “Out-of-network” means you’ll likely pay more.

Insurance companies negotiate contracts with hospitals and other medical providers to set the rates they will pay for various services. When they reach an agreement, the hospital and most of the providers who work there become part of the insurance company’s network.

Most patients prefer to see providers who are “in-network” because their insurance picks up some, most, or even all of the bill, which could be hundreds or thousands of dollars. If you see an out-of-network provider, you could be on the hook for the whole tab.

If you decide to stick with your familiar doctors even though they’re out-of-network, consider asking about getting a cash discount and about the hospital’s financial assistance program.

2. Rifts between hospitals and insurers often get repaired.

When Brown University health policy researcher Jason Buxbaum examined 3,714 nonfederal hospitals across the U.S., he said, he found that about 18% of them had a public dispute with an insurance company sometime from June 2021 to May 2025.

About half of those hospitals ultimately dropped out of the insurance company’s network, according to Buxbaum’s preliminary data. But most of those breakups ultimately get resolved within a month or two, he added. So your doctors very well could end up back in the network, even after a split.

3. You might qualify for an exception to keep costs lower.

Certain patients with serious or complex conditions might qualify for an extension of in-network coverage, called continuity of care. You can apply for that extension by contacting your insurer, but the process may prove lengthy. Some hospitals have set up resources to help patients apply for that extension.

Wingler ran that gantlet for her daughter, spending hours on the phone, filling out forms, and sending faxes. But she said she didn’t have the time or energy to do that for everyone in her family.

“My son was going through physical therapy,” she said. “But I’m sorry, dude, like, just do your exercises that you already have. I’m not fighting to get you coverage too, when I’m already fighting for your sister.”

Also worth noting, if you’re dealing with a medical emergency: For most emergency services, hospitals can’t charge patients more than their in-network rates.

4. Switching your insurance carrier may need to wait.

You might be thinking of switching to an insurer that covers your preferred doctors. But be aware: Many people who choose their insurance plans during an annual open enrollment period are locked into their plan for a year. Insurance contracts with hospitals are not necessarily on the same timeline as your “plan year.”

Certain life events, such as getting married, having a baby, or losing a job, can qualify you to change insurance outside of your annual open enrollment period, but your doctors’ dropping out of an insurance network is not a qualifying life event.

5. Doctor-shopping can be time-consuming.

If the split between your insurance company and hospital looks permanent, you might consider finding a new slate of doctors and other providers who are in-network with your plan. Where to start? Your insurance plan likely has an online tool to search for in-network providers near you. 

But know that making a switch could mean waiting to establish yourself as a patient with a new doctor and, in some cases, traveling a fair distance.

6. It’s worth holding on to your receipts.

Even if your insurance and hospital don’t strike a deal before their contract expires, there’s a decent chance they will still make a new agreement.

Some patients decide to put off appointments while they wait. Others keep their appointments and pay out-of-pocket. Hold on to your receipts if you do. When insurers and hospitals make up, the deals often are backdated, so the appointments you paid for out-of-pocket could be covered after all.

End of an Ordeal

Three months after the contract between Wingler’s insurance company and the hospital lapsed, the sides announced they had reached a new agreement. Wingler joined the throng of patients scheduling appointments they’d delayed during the ordeal.

In a statement, Jim Turner, a spokesperson for Anthem’s parent company, Elevance Health, wrote, “We approach negotiations with a focus on fairness, transparency, and respect for everyone impacted.”

Maze from MU Health Care said: “We understand how important timely access to pediatric specialty care is for families, and we’re truly sorry for the frustration some parents have experienced scheduling appointments following the resolution of our Anthem contract negotiations.”

Wingler was happy her family could see their providers again, but her relief was tempered by a resolve not to be caught in the same position again.

“I think we will be a little more studious when open enrollment comes around,” Wingler said. “We’d never really bothered to look at our out-of-pocket coverage before because we didn’t need it.”

Author: Bram Sable-Smith: brams@kff.org, @besables

Illustrations: Oona Zenda: ozenda@kff.org

The post So Your Insurance Dropped Your Doctor. Now What? appeared first on Medika Life.